Tryptamine Therapeutics (AU:TYP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics Limited, a biotech firm specializing in novel psilocin formulations for psychotherapy, has announced its AGM to be held on November 8, 2024, with director nominations closing on September 27. The company has reported significant clinical advancements with TRP-8803, showing promise in treating binge eating disorder and is currently exploring treatments for fibromyalgia and irritable bowel syndrome. Interested parties can find more information on the company’s progress and clinical trials on their website.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.